Fig. 2From: Discontinuation risk from adverse events: immunotherapy alone vs. combined with chemotherapy: a systematic review and network meta-analysisNetwork plot illustrating comparisons of the risk of discontinuation due to TRAEs among different treatments(A) For various cancer types, (B) For the NSCLC subgroupBack to article page